HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: ard.2006.055269v1 ard.2006.055269v2 65/10/1312    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, W Articles by Zimmermann-Gòrska, I Search for Related Content PubMed PubMed Citation Articles by Zhang, W Articles by Zimmermann-Gòrska, I Topic Collections Related Article

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)

¹ Academic Rheumatology, University of Nottingham, Nottingham, UK
² Sección de Rheumatologia, Hospital General Universitario de Alicante, Alicante, Spain
³ Fédération de Rhumatologie, Hôpital Lariboisière, Paris, France
⁴ Institute of Rheumatology RAMS, Moscow, Russian Federation
⁵ Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, UK
⁶ Service de Rhumatologie, Hôpital Nestlé, CH 1011 Lausanne-CHUV, Switzerland
⁷ Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, Netherlands
⁸ Second Department of Medicine, Lower Austrian Centre for Rheumatology, Stockerau, Austria
⁹ Fédération de Rhumatologie and INSERM U606, IFR 139, Hôpital Lariboisière, Paris, France
¹⁰ Division of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland
¹¹ U7R7561 CNR-UHP, Physiopathologie et Pharmacologie Articulaire, Universite Henri Poincare, Vandoeuvre Les Nancy, France
¹² Osteoarticular Research Group, University of Edinburgh, Edinburgh, UK
¹³ Sección de Rheumatologia, Hospital de Cruces, Baracaldo, Spain
¹⁴ Departmento Medicina Interna, University of Florence, Florence, Italy
¹⁵ Rheumatology Unit, Hospital Egas Moniz, Lisbon, Portugal
¹⁶ Rheumatology Unit, University of Padova, Padova, Italy
¹⁷ Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
¹⁸ Department of Rheumatology, Rehabilitation and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland

Correspondence to:
Correspondence to:
Dr W Zhang
Academic Rheumatology, University of Nottingham, Clinical Sciences Building, City Hospital, Nottingham NG5 1PB, UK; weiya.zhang{at}nottingham.ac.uk

Objective: To develop evidence based recommendations for the management of gout.

Methods: The multidisciplinary guideline development group comprised 19 rheumatologists and one evidence based medicine expert representing 13 European countries. Key propositions on management were generated using a Delphi consensus approach. Research evidence was searched systematically for each proposition. Where possible, effect size (ES), number needed to treat, relative risk, odds ratio, and incremental cost-effectiveness ratio were calculated. The quality of evidence was categorised according to the level of evidence. The strength of recommendation (SOR) was assessed using the EULAR visual analogue and ordinal scales.

Results: 12 key propositions were generated after three Delphi rounds. Propositions included both non-pharmacological and pharmacological treatments and addressed symptomatic control of acute gout, urate lowering therapy (ULT), and prophylaxis of acute attacks. The importance of patient education, modification of adverse lifestyle (weight loss if obese; reduced alcohol consumption; low animal purine diet) and treatment of associated comorbidity and risk factors were emphasised. Recommended drugs for acute attacks were oral non-steroidal anti-inflammatory drugs (NSAIDs), oral colchicine (ES = 0.87 (95% confidence interval, 0.25 to 1.50)), or joint aspiration and injection of corticosteroid. ULT is indicated in patients with recurrent acute attacks, arthropathy, tophi, or radiographic changes of gout. Allopurinol was confirmed as effective long term ULT (ES = 1.39 (0.78 to 2.01)). If allopurinol toxicity occurs, options include other xanthine oxidase inhibitors, allopurinol desensitisation, or a uricosuric. The uricosuric benzbromarone is more effective than allopurinol (ES = 1.50 (0.76 to 2.24)) and can be used in patients with mild to moderate renal insufficiency but may be hepatotoxic. When gout is associated with the use of diuretics, the diuretic should be stopped if possible. For prophylaxis against acute attacks, either colchicine 0.5–1 mg daily or an NSAID (with gastroprotection if indicated) are recommended.

Conclusions: 12 key recommendations for management of gout were developed, using a combination of research based evidence and expert consensus. The evidence was evaluated and the SOR provided for each proposition.

Abbreviations: AHS, allopurinol hypersensitivity syndrome; ES, effect size; ESCISIT, EULAR Standing Committee for International Clinical Studies Including Therapeutics; EULAR, European League Against Rheumatism; ICER, incremental cost-effectiveness ratio; NNT, number needed to treat; NSAID, non-steroidal anti-inflammatory drug; QALY, quality of life years; RCT, randomised controlled trial; SOR, strength of recommendation; SUA, serum uric acid; VAS, visual analogue scale

Keywords: EULAR; gout; guidelines; treatment

Related Article

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT)

W Zhang, M Doherty, E Pascual, T Bardin, V Barskova, P Conaghan, J Gerster, J Jacobs, B Leeb, F Lioté, G McCarthy, P Netter, G Nuki, F Perez-Ruiz, A Pignone, J Pimentão, L Punzi, E Roddy, T Uhlig, and I Zimmermann-Gòrska
Ann Rheum Dis 2006 65: 1301-1311. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				M K Reinders and T L T. A Jansen Survey on management of gout among Dutch rheumatologists Ann Rheum Dis, July 1, 2008; 67(7): 1049 - 1049. [Full Text] [PDF]

				L Annemans, E Spaepen, M Gaskin, M Bonnemaire, V Malier, T Gilbert, and G Nuki Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005 Ann Rheum Dis, July 1, 2008; 67(7): 960 - 966. [Abstract] [Full Text] [PDF]

				M Doherty, T Bardin, and E Pascual International survey on the diagnosis and management of gout Ann Rheum Dis, December 1, 2007; 66(12): 1685 - 1686. [Full Text] [PDF]

				J N Hoes, J W G Jacobs, M Boers, D Boumpas, F Buttgereit, N Caeyers, E H Choy, M Cutolo, J A P Da Silva, G Esselens, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases Ann Rheum Dis, December 1, 2007; 66(12): 1560 - 1567. [Abstract] [Full Text] [PDF]

				E. Pascual and F. Sivera Why is gout so poorly managed? Ann Rheum Dis, October 1, 2007; 66(10): 1269 - 1270. [Full Text] [PDF]

				E. Roddy, W. Zhang, and M. Doherty Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations Ann Rheum Dis, October 1, 2007; 66(10): 1311 - 1315. [Abstract] [Full Text] [PDF]